EN DE
Watch Jia Jie Biomedical Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Jia Jie Biomedical Co Ltd (4109) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Jia Jie Biomedical Co Ltd stock TWD 5.72, price TWD 10.20, that is 43.9% below the price, quality 17 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive TW · ISIN TW0004109004

JJ Jia Jie Biomedical Co Ltd logo Thin data Nov 9, 2026

Jia Jie Biomedical Co Ltd

4109 · TWO
Very expensive, weak quality

Our calculation puts a fair price 44% below what the stock costs today.

Low debt
Last quarter vs. a year ago: revenue +26%, profit +25%.
Expensive Growth (revenue 5y +12.4 %/yr in TWD)
Thin margins · 0.6% net margin (TTM)
Fair value 5.72 TWD · Strongly overvalued
Quality 17/100
Negative free cash flow
2.0% dividend yield · Pays more than it earns
Trails peers (3/12)
Narrow moat 29/100
Thin data
⚠ Dilution
Watch Jia Jie Biomedical Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

34.77 TWD 10.10 TWD Fair Value 5.72 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range 10.10 TWD – 34.77 TWD · fair‑value band 4.00 TWD – 7.43 TWD · the 10.20 TWD price screens above the 5.72 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Jia Jie Biomedical Co in your weekly email

Every Wednesday you see whether Jia Jie Biomedical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage.

Show moreShow less

The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jelly, softshell turtle oil, and powder capsules; and import and export, distribution, bidding, quotation of the products.

It also involved in the wholesale of nonalcoholic beverages, candy, baked food, supplementary food, groceries, daily commodities, and cosmetics; production of water purification equipment and related parts; life and property insurance brokerage business; development and production of aquatic product technology; and development of biological products.

The company was formerly known as Murad Chia Jei Biotechnology Co., Ltd. and changed its name to Jia Jie Biomedical Co., Ltd. in June 2019. Jia Jie Biomedical Co., Ltd. was founded in 1995 and is based in Kaohsiung, Taiwan.

Stock analysis

Jia Jie Biomedical Co Ltd (4109) currently trades at 10.20 TWD, while our model-based Fair Value estimate is 5.72 TWD, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 7.72 TWD per share, and 1 of the 12 models we run sit above the 10.20 TWD price.

Bear case: the Earnings-Based group reads lowest at 3.04 TWD, and 11 of the 12 models stay below the price. Data coverage for this calculation is low.

Scenario range: 4.00 TWD (bear) to 7.43 TWD (bull), the price of 10.20 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 17/100 (below-average quality), in the Consumer Defensive sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Jia Jie Biomedical Co Ltd reported revenue of 485M TWD in FY2025 versus 242M TWD in FY2021, a compound +18.9%/yr. Reported net income was 50.3M TWD in FY2025, compounding +75.2%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Key figures

Market cap 1.2B TWD (≈ $36.9M) Micro · P/E ratio 340.0 · P/S ratio 2.35 · EPS (TTM) 0.0300 TWD · Dividend yield 2.0% · Net margin 0.6% · Return on equity 0.2% · Return on assets (EBIT) −0.8% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (medium confidence).

What moves the price

The share trades about 36% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at −44%, 4109 screens richer than that median.

Fair Value models

Bear 4.00 TWD Fair Value 5.72 TWD Bull 7.43 TWD
Price 10.20 TWD · Downside -43.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 9.88 TWD 9.82 TWD 10.02 TWD 76
EPV 2.53 TWD 2.54 TWD 2.54 TWD 74
ROIC Compounder 2.53 TWD 2.54 TWD 2.54 TWD 72
All 12 models by family
Earnings-Based
Graham-Dodd 2.88 TWD 3.53 TWD 3.98 TWD 67
EPV 2.53 TWD 2.54 TWD 2.54 TWD 74
Dividend Discount
Gordon GGM 4.11 TWD 4.45 TWD 4.97 TWD 69
DDM Multi-Stage 4.11 TWD 4.98 TWD 6.13 TWD 67
Multiples
P/E Multiple 6.67 TWD 8.89 TWD 11.11 TWD 63
P/S Multiple 4.91 TWD 6.54 TWD 8.18 TWD 58
P/B Multiple 15.97 TWD 21.30 TWD 26.62 TWD 55
EV/EBITDA 0.2800 TWD 0.7800 TWD 1.28 TWD 62
Asset-Based
NCAV (Graham) 2.05 TWD 3.11 TWD 3.89 TWD 54
Economic Profit
Residual Income 9.88 TWD 9.82 TWD 10.02 TWD 76
ROIC Compounder 2.53 TWD 2.54 TWD 2.54 TWD 72
Growth Earnings
Growth-Adj P/E 4.71 TWD 6.73 TWD 8.74 TWD 67

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 17/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 7
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 4
Does it invest with discipline instead of growing at any price?
Low Volatility 87
How calm the share price moves, does not count
Price momentum 24
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 49/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−9.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Start year 2020 (pandemic). Over 10 years: −4.8% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.8%
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+49.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+47.8%
Dividend (yield on the price)2.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−18% → 0%
⚠ Revenue per share shrinking 5.7%/yr over ~6Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

4109 screens overvalued: fair value 44% below the price. Compare with Nestlé S.A →

Compare Jia Jie Biomedical Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 627 stocks

Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 17 · Bottom 25%
Fair Value upside −43.9% · Bottom 25%
Profitability
Return on equity (12 months) 0.2% · Bottom 25%
Return on assets 2.7% · Below median
Net margin (12 months) 0.6% · Bottom 25%
Operating margin (12 months) −0.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 25.5% · Top 25%
Dividend yield (12 months) 2.0% · Below median

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/E (12 months) 340.0× · Priciest 25%
P/B 0.72× · Cheapest 25%
P/S (12 months) 2.35× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 36
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)1 · sector 31
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)39 · sector 55

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wilmar International Limited F34 2.97 SGD 4.93 SGD +66% vs 4109
Inner Mongolia Yili Industrial Group 600887 ¥31.14 ¥41.84 +34% vs 4109
The Kraft Heinz Company KHC $24.61 $29.20 +19% vs 4109
Foshan Haitian Flavouring and Food Company 603288 ¥35.26 ¥39.22 +11% vs 4109
General Mills, Inc GIS $35.51 $35.30 −1% vs 4109
Danone S.A BN €67.66 €50.65 −25% vs 4109
Nestlé S.A NESN CHF 86.13 CHF 59.51 −31% vs 4109
Kerry Group KRZ €97.15 €60.33 −38% vs 4109
Nestlé India Limited NESTLEIND ₹1,298 ₹724.74 −44% vs 4109
Yihai Kerry Arawana Holdings 300999 ¥26.14 ¥12.21 −53% vs 4109

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jia Jie Biomedical Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jia Jie Biomedical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4109

Frequently asked questions

Is Jia Jie Biomedical Co Ltd (4109) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 5.72 TWD versus a price of 10.20 TWD, about 44% lower (overvalued).
What is the fair value of 4109?
Our model-based fair value for Jia Jie Biomedical Co Ltd is 5.72 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 10.20 TWD.
What is the quality score of 4109?
Jia Jie Biomedical Co Ltd has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jia Jie Biomedical Co Ltd (4109)?
Our model-based price target is the fair value of 5.72 TWD (as of Nov 9, 2026) from 12 valuation models. Cautious scenario 4.00 TWD, optimistic scenario 7.43 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Jia Jie Biomedical Co Ltd stock forecast for 2026?
Our models put fair value at 5.72 TWD, about 44% lower versus a price of 10.20 TWD (overvalued). Cautious scenario 4.00 TWD, optimistic scenario 7.43 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Jia Jie Biomedical Co Ltd (4109)?
Jia Jie Biomedical Co Ltd reported trailing-twelve-month revenue of about 515M TWD (latest available figure, as of Nov 9, 2026).
Does Jia Jie Biomedical Co Ltd pay a dividend?
Jia Jie Biomedical Co Ltd currently shows a dividend yield of 1.96% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Jia Jie Biomedical Co Ltd (4109) and when is the ex-dividend date?
Jia Jie Biomedical Co Ltd pays a dividend of 0.2 TWD per share a year, a dividend yield of 2.0%. The last ex-dividend date was Sep 23, 2026. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Jia Jie Biomedical Co Ltd (4109)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jia Jie Biomedical Co Ltd it is 5.72 TWD per share (as of Nov 9, 2026), against a price of 10.20 TWD. It is the blended result of 12 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Jia Jie Biomedical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 4109 trades above its calculated fair value: price 10.20 TWD, fair value 5.72 TWD, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4109?
No. The price is what the market pays today (10.20 TWD); the fair value is what the company's own numbers justify (5.72 TWD). For Jia Jie Biomedical Co Ltd the two are 4.48 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Jia Jie Biomedical Co Ltd worth?
The market values Jia Jie Biomedical Co Ltd at about 1.2B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 10.20 TWD; our models calculate a fair value of 5.72 TWD per share.
What do the bullish and bearish scenarios say about 4109?
Our models span a range for Jia Jie Biomedical Co Ltd: cautious scenario 4.00 TWD, base 5.72 TWD, optimistic 7.43 TWD per share (as of Nov 9, 2026, price 10.20 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4109?
Jia Jie Biomedical Co Ltd trades at a price-to-earnings ratio of 340.0 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 5.72 TWD is built from several models across several years. Other multiples: P/B 0.7, P/S 2.4.
How solid is the balance sheet of Jia Jie Biomedical Co Ltd (4109)?
Balance-sheet figures for Jia Jie Biomedical Co Ltd (as of Nov 9, 2026): return on equity 0.2%. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is 4109 from its 52-week high?
Jia Jie Biomedical Co Ltd trades at 10.20 TWD, about 36% below its 52-week high of 15.91 TWD and 1% above the low of 10.10 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 5.72 TWD is for.
Which stocks are comparable to Jia Jie Biomedical Co Ltd?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jia Jie Biomedical Co Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 10.20 TWD, calculated fair value 5.72 TWD (−44%), Quality Score 17/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4109 calculated?
We run Jia Jie Biomedical Co Ltd through 12 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5.72 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Jia Jie Biomedical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jia Jie Biomedical Co Ltd (4109)?
The closing price on Nov 9, 2026 was 10.20 TWD. Our model-based fair value is 5.72 TWD, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jia Jie Biomedical Co Ltd right now?
The price sits above even our optimistic bull case (7.43 TWD). The favourable scenario is already priced in. Weak quality (17/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (4.00 TWD to 7.43 TWD) leaves room in how you read the outcome.

Key figures of Jia Jie Biomedical Co Ltd

How large is the market capitalisation of Jia Jie Biomedical Co Ltd (4109)?
The market capitalisation of Jia Jie Biomedical Co Ltd is 1.2B TWD (≈ $36.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jia Jie Biomedical Co Ltd (4109)?
The price-to-sales ratio of Jia Jie Biomedical Co Ltd is 2.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jia Jie Biomedical Co Ltd (4109)?
Earnings per share at Jia Jie Biomedical Co Ltd are 0.0300 TWD (price ÷ EPS = P/E 340.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jia Jie Biomedical Co Ltd (4109)?
The dividend yield of Jia Jie Biomedical Co Ltd is 2.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jia Jie Biomedical Co Ltd (4109)?
The net margin of Jia Jie Biomedical Co Ltd is 0.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jia Jie Biomedical Co Ltd (4109)?
The return on equity (ROE) of Jia Jie Biomedical Co Ltd is 0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jia Jie Biomedical Co Ltd (4109)?
On an EBIT basis the return on assets of Jia Jie Biomedical Co Ltd is −0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jia Jie Biomedical Co Ltd (4109)?
The operating margin of Jia Jie Biomedical Co Ltd is −0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jia Jie Biomedical Co Ltd (4109)?
Revenue at Jia Jie Biomedical Co Ltd is growing +25.5% versus a year earlier (3y avg +15.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jia Jie Biomedical Co Ltd (4109)?
Earnings per share at Jia Jie Biomedical Co Ltd are growing +25.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jia Jie Biomedical Co Ltd (4109) generate?
The free cash flow of Jia Jie Biomedical Co Ltd is −64.2M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jia Jie Biomedical Co Ltd (4109) carry?
The net debt of Jia Jie Biomedical Co Ltd is 144M TWD (fiscal year 2018). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Jia Jie Biomedical Co Ltd in the live analysis

One click puts Jia Jie Biomedical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.